MétaCan
← all works

Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study

2010· article· en· 426 citations· W2165467426 on OpenAlex· 10.1177/0333102410381142

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

Canadian funderA Canadian agency funded it. The work may carry no Canadian affiliation at all.

No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.

Machine scores (provisional)

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Opus teacher head0.041
GPT teacher head0.352
Teacher spread
0.311 · how far apart the two teachers sit on this one work
Validation status
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Abstract

BACKGROUND: Medically intractable chronic migraine (CM) is a disabling illness characterized by headache ≥15 days per month. METHODS: A multicenter, randomized, blinded, controlled feasibility study was conducted to obtain preliminary safety and efficacy data on occipital nerve stimulation (ONS) in CM. Eligible subjects received an occipital nerve block, and responders were randomized to adjustable stimulation (AS), preset stimulation (PS) or medical management (MM) groups. RESULTS: Seventy-five of 110 subjects were assigned to a treatment group; complete diary data were available for 66. A responder was defined as a subject who achieved a 50% or greater reduction in number of headache days per month or a three-point or greater reduction in average overall pain intensity compared with baseline. Three-month responder rates were 39% for AS, 6% for PS and 0% for MM. No unanticipated adverse device events occurred. Lead migration occurred in 12 of 51 (24%) subjects. CONCLUSION: The results of this feasibility study offer promise and should prompt further controlled studies of ONS in CM.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

The record

Venue
Cephalalgia
Topic
Migraine and Headache Studies
Field
Medicine
Canadian institutions
Funders
National Institute of Neurological Disorders and StrokeAllerganKowa CompanyH. Lundbeck A/SPurdue PharmaSt. Jude MedicalNeuroscience Research AustraliaValeant Pharmaceuticals InternationalGlaxoSmithKlineZogenixBoston Scientific CorporationPfizerPurdue UniversityEli Lilly and Company
Keywords
MedicineOccipital nerve stimulationMigraineChronic MigraineMigraine DisordersOccipital neuralgiaStimulationAnesthesiaPhysical medicine and rehabilitationPhysical therapyNeuralgiaAlternative medicineInternal medicineNeuropathic painPathology
Has abstract in OpenAlex
yes